LAMISIL AT Drug Patent Profile
✉ Email this page to a colleague
When do Lamisil At patents expire, and what generic alternatives are available?
Lamisil At is a drug marketed by Karo Hlthcare and is included in two NDAs.
The generic ingredient in LAMISIL AT is terbinafine hydrochloride. There are twenty-seven drug master file entries for this compound. Forty-one suppliers are listed for this compound. Additional details are available on the terbinafine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Lamisil At
A generic version of LAMISIL AT was approved as terbinafine hydrochloride by TARO on July 2nd, 2007.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for LAMISIL AT?
- What are the global sales for LAMISIL AT?
- What is Average Wholesale Price for LAMISIL AT?
Summary for LAMISIL AT
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 91 |
| Clinical Trials: | 19 |
| Patent Applications: | 4,479 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for LAMISIL AT |
| DailyMed Link: | LAMISIL AT at DailyMed |
Recent Clinical Trials for LAMISIL AT
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| The Malassezia Foundation | Early Phase 1 |
| Oregon Health and Science University | Early Phase 1 |
| Pak Emirates Military Hospital | Phase 3 |
US Patents and Regulatory Information for LAMISIL AT
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Karo Hlthcare | LAMISIL AT | terbinafine | GEL;TOPICAL | 021958-001 | Jul 24, 2006 | OTC | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Karo Hlthcare | LAMISIL AT | terbinafine hydrochloride | SOLUTION;TOPICAL | 021124-001 | Mar 17, 2000 | OTC | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Karo Hlthcare | LAMISIL AT | terbinafine hydrochloride | SPRAY;TOPICAL | 021124-002 | Mar 17, 2000 | OTC | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for LAMISIL AT
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Karo Hlthcare | LAMISIL AT | terbinafine hydrochloride | SOLUTION;TOPICAL | 021124-001 | Mar 17, 2000 | ⤷ Sign Up | ⤷ Sign Up |
| Karo Hlthcare | LAMISIL AT | terbinafine hydrochloride | SPRAY;TOPICAL | 021124-002 | Mar 17, 2000 | ⤷ Sign Up | ⤷ Sign Up |
| Karo Hlthcare | LAMISIL AT | terbinafine | GEL;TOPICAL | 021958-001 | Jul 24, 2006 | ⤷ Sign Up | ⤷ Sign Up |
| Karo Hlthcare | LAMISIL AT | terbinafine | GEL;TOPICAL | 021958-001 | Jul 24, 2006 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for LAMISIL AT
See the table below for patents covering LAMISIL AT around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Ireland | 781670 | ⤷ Sign Up | |
| Australia | 3908278 | ⤷ Sign Up | |
| Ireland | 47314 | PROPENYL AMINES,PROCESSES FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ⤷ Sign Up |
| Finland | 782446 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for LAMISIL AT
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0024587 | 93C0136 | Belgium | ⤷ Sign Up | PRODUCT NAME: TERBINAFINE (250 MG) SOUS FORME DE CHLORHYDRATE (281,25 MG); NAT. REG.: 616 S 201 F3 19911031; FIRST REG.: GB PL 0101/0304 19901003 |
| 0024587 | SPC/GB93/096 | United Kingdom | ⤷ Sign Up | SPC/GB93/096, EXPIRES: 20050805 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
